4SC Further Strengthens Patent Protection for its Lead Compound Resminostat

4SC AG has announced that the company has further strengthened the patent protection for its lead anti-cancer compound resminostat.

The US Patent Office has granted the patent for resminostat's manufacturing process. The patent, which runs until 20 July 2029, protects the chemical process used in the manufacture of resminostat. This constitutes an additional obstacle for potential competitors while further extending the total term of resminostat's portfolio of property rights.

Overall, this means the resminostat manufacturing process is protected until 2029 in almost all key markets around the world, including Europe, Japan, China, Russia, Hong Kong, Singapore and Australia - and now the USA.

This supplements worldwide protection for resminostat's strategically important composition-of-matter patent, which was achieved on a global basis already in 2013.

Enno Spillner, Chief Executive Officer of 4SC, said: "We are pleased to announce the protection of the resminostat manufacturing method in the world's most important markets, in addition to its material composition. This contributes another strategically important element to our lead compound's patent portfolio. We believe it is important to take action sufficiently early to prepare resminostat for a subsequent global marketing strategy."